The FDA has recently approved two medications for chronic weight management in adults with obesity or overweight. The first medication is Zepbound (tirzepatide) injection, which is approved for use in adults with obesity or overweight with at least one weight-related condition, in addition to a reduced-calorie diet and increased physical activity
. The second medication is Ozempic (semaglutide), which was originally approved for use in adults with type 2 diabetes but has also been found to work for weight loss. It is important to note that Ozempic is not approved for weight loss, but some physicians prescribe it off-label for this purpose
. Additionally, semaglutide is approved for weight loss under the name Wegovy
. Both medications have shown significant weight loss results in clinical trials, with Zepbound helping people lose, on average, 52 pounds and Ozempic leading to an average weight loss of about 34 pounds after 68 weeks
. The active ingredients in these medications mimic hormones that help reduce food cravings and improve how the body breaks down sugar and fat, leading to amplified weight loss effects
. It's important to consult a healthcare provider for detailed product information, including positive and negative aspects, and to understand the ingredients or materials used in these medications.
